OR6B1 Inhibitors
OR6B1 inhibitors belong to a specific category of chemical compounds that are designed to selectively bind to and inhibit the function of a particular olfactory receptor, OR6B1. Olfactory receptors are a group of G-protein-coupled receptors (GPCRs) that are primarily recognized for their role in the sense of smell. These receptors are found in the cell membranes of olfactory sensory neurons and are responsible for detecting volatile odorant molecules. The OR6B1 receptor is one of the many receptors in the olfactory system that contributes to the complex process of odor detection and signal transduction. Inhibition of OR6B1 involves the binding of these inhibitor molecules to the receptor, which prevents the receptor from interacting with its natural ligands – the odorant molecules. This interaction between the inhibitor and the receptor takes place at the binding site, which is typically a highly specific region of the protein that accommodates the molecular structure of the inhibitor.
The design of OR6B1 inhibitors is a sophisticated process that requires detailed knowledge of the molecular structure and function of the OR6B1 receptor. Researchers utilize various techniques such as X-ray crystallography, molecular modeling, and ligand-binding assays to determine the three-dimensional structure of the receptor and to identify key binding pockets that can be targeted by inhibitors. OR6B1 inhibitors are synthesized through organic chemistry protocols that may involve multiple steps of chemical reactions to achieve the desired specificity and binding affinity. The inhibitors are characterized by their ability to bind to the OR6B1 receptor with high specificity, thereby preventing the receptor from being activated by its natural ligands. The selectivity of these inhibitors is crucial, as it ensures minimal off-target effects, given the vast array of similar receptors in the olfactory system. These chemical compounds are often used in research to elucidate the signaling pathways and functions associated with the OR6B1 receptor by observing the outcomes of receptor inhibition under various experimental conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palmitoleic acid | 373-49-9 | sc-205424 sc-205424A sc-205424B sc-205424C sc-205424D | 100 mg 500 mg 1 g 5 g 10 g | $32.00 $132.00 $233.00 $1019.00 $1870.00 | 4 | |
Palmitoleic acid is a monounsaturated fatty acid that can incorporate into cell membranes, altering membrane fluidity and potentially affecting G protein-coupled receptor (GPCR) function. Since OR6B1 is a member of the GPCR family, changes in membrane composition could influence OR6B1’s structure and thereby its activity by affecting ligand binding or G protein interaction. | ||||||
Cholesterol | 57-88-5 | sc-202539C sc-202539E sc-202539A sc-202539B sc-202539D sc-202539 | 5 g 5 kg 100 g 250 g 1 kg 25 g | $26.00 $2754.00 $126.00 $206.00 $572.00 $86.00 | 11 | |
Cholesterol is a major component of cellular membranes and can modulate membrane fluidity. It plays a crucial role in the formation of lipid rafts, which are known to cluster certain types of GPCRs and can thereby affect their signaling. As OR6B1 is a GPCR, increased cholesterol levels can potentially alter its localization and impair its signaling capacity. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
Pertussis toxin irreversibly ADP-ribosylates the alpha subunit of the Gi/o type G proteins, preventing interaction with GPCRs. As OR6B1 is presumed to signal through Gi/o proteins, pertussis toxin would inhibit OR6B1-mediated signaling by preventing proper G protein-coupling, leading to a decrease in its functional activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin is an activator of adenylyl cyclase, leading to an increase in cyclic AMP (cAMP) levels in cells. Elevated cAMP may lead to the activation of protein kinase A (PKA), which can phosphorylate and desensitize GPCRs, including OR6B1, thereby decreasing its activity. | ||||||
2-Bromohexadecanoic acid | 18263-25-7 | sc-251714 sc-251714A | 10 g 50 g | $52.00 $197.00 | 4 | |
2-Bromopalmitate is a palmitate analog that inhibits protein palmitoylation, a post-translational modification that can affect GPCR trafficking and localization. Inhibition of palmitoylation could, therefore, interfere with proper localization and function of OR6B1 on the cell surface. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic receptor antagonist that may also interact with other GPCRs and alter their function. While it is not a direct inhibitor of OR6B1, propranolol may compete for similar downstream signaling pathways or molecules, leading to an indirect inhibition of OR6B1’s activity. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A | 50 mg 500 mg | $68.00 $357.00 | 11 | |
Clozapine is an atypical antipsychotic known to interact with a variety of GPCRs. As a GPCR, OR6B1 may be indirectly affected by clozapine through alterations in cellular signaling pathways shared among GPCRs, possibly leading to a decrease in OR6B1-mediated signaling. | ||||||
VPC 23019 | 449173-19-7 | sc-362817 | 10 mg | $357.00 | 4 | |
VPC 23019 is a sphingosine-1-phosphate receptor antagonist. While it does not directly target OR6B1, it may modulate the signaling environment in which OR6B1 operates, potentially leading to indirect inhibition of OR6B1 signaling through shared signaling components or regulatory mechanisms. | ||||||
NF 023 | 104869-31-0 | sc-204124 sc-204124A | 10 mg 50 mg | $158.00 $617.00 | 1 | |
NF023 is a selective antagonist of the P2X1 purinergic receptor but may also influence other purinergic receptors and their signaling pathways. Given the interconnectivity of GPCR signaling pathways, NF023 could indirectly affect OR6B1 activity by altering the balance of purinergic and GPCR signaling. | ||||||